Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention
Public ClinicalTrials.gov record NCT03238781. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a Randomized Double-blind Placebo Controlled Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention
Study identification
- NCT ID
- NCT03238781
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Amgen
- Industry
- Enrollment
- 343 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- AMG 301 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 5, 2017
- Primary completion
- Oct 15, 2018
- Completion
- Feb 3, 2019
- Last update posted
- Feb 6, 2020
2017 – 2019
United States locations
- U.S. sites
- 21
- U.S. states
- 13
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Long Beach | California | 90806 | — |
| Research Site | Santa Monica | California | 90404 | — |
| Research Site | Boulder | Colorado | 80301 | — |
| Research Site | East Hartford | Connecticut | 06118 | — |
| Research Site | Stamford | Connecticut | 06905 | — |
| Research Site | Jacksonville | Florida | 32216 | — |
| Research Site | Orlando | Florida | 32801 | — |
| Research Site | West Palm Beach | Florida | 33407 | — |
| Research Site | Worcester | Massachusetts | 01605 | — |
| Research Site | Ann Arbor | Michigan | 48104 | — |
| Research Site | City of Saint Peters | Missouri | 63303 | — |
| Research Site | St Louis | Missouri | 63141 | — |
| Research Site | Plainview | New York | 11803 | — |
| Research Site | Greensboro | North Carolina | 27405 | — |
| Research Site | Cleveland | Ohio | 44195 | — |
| Research Site | Memphis | Tennessee | 38119 | — |
| Research Site | Nashville | Tennessee | 37203 | — |
| Research Site | Austin | Texas | 78731 | — |
| Research Site | Dallas | Texas | 75214 | — |
| Research Site | Round Rock | Texas | 78681 | — |
| Research Site | Salt Lake City | Utah | 84109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03238781, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 6, 2020 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03238781 live on ClinicalTrials.gov.